Drug Search Results
More Filters [+]

Tazobactam

Alternative Names: tazobactam, zosyn, zerbaxa
Latest Update: 2024-10-09
Latest Update Note: News Article

Product Description

Piperacillin and tazobactam combination injection is used to treat bacterial infections in many different parts of the body (eg, stomach or bowel, lungs, skin, female reproductive organs). (Sourced from: https://www.mayoclinic.org/drugs-supplements/piperacillin-and-tazobactam-intravenous-route/description/drg-20072716)

Mechanisms of Action: LACTB Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Pneumonia, Bacterial | Pelvic Infection | Pneumonia | Urinary Tract Infections | Nephritis | Pyelonephritis

Known Adverse Events: Headache | Insomnia | Constipation | Diarrhea

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tazobactam

Countries in Clinic: Australia, Belgium, Canada, Chile, China, Colombia, Croatia, Estonia, Germany, Greece, Hungary, India, Ireland, Japan, Mexico, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Russia, Saudi Arabia, Spain, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: COVID-19|Enterobacteriaceae Infections|Influenza, Human|Pneumonia|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated

Phase 2: Bacteremia|Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Coinfection|Community-Acquired Infections|Pseudomonas Infections|Pyelonephritis|Respiratory Tract Infections|Urinary Tract Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

REMAP-CAP

P3

Recruiting

Influenza, Human|Pneumonia|COVID-19

2026-02-01

NCT04673175

P2

Recruiting

Pneumonia|Pseudomonas Infections|Bacteremia

2025-12-31

2022-002636-31

P3

Active, not recruiting

Enterobacteriaceae Infections

2025-12-09

FRENCH24 ANIS

P3

Active, not recruiting

Unknown

2025-04-03

Recent News Events